File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: How have we treated pathological T1 (pT1) prostate cancer (CaP) in recent 10 years?

TitleHow have we treated pathological T1 (pT1) prostate cancer (CaP) in recent 10 years?
Authors
Issue Date2014
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
Hong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 8 How to Cite?
AbstractObjective: To review the treatment modality and outcome of patients with pT1 CaP. Patients & Methods: Data of transurethral resection of prostate (TURP) performed from April 2000 to December 2009 were reviewed. Pathological results of resected specimen were reviewed on electronic patient record (ePR) system and data of patients with pT1 CaP were retrieved. Kaplan-Meier model was used to compare survival. Results: During the period, 178 patients were diagnosed pT1 prostate cancer with median follow-up time of 57.5 months. Median age at TURP was 77 years old. 97 (54.5%) patients had pT1a CaP and 65 (36.5%) had pT1b CaP; extent of tumour involvement was not reported in 16 (9%) specimens. 9 (5.1%) patients underwent curative treatment – radical prostatectomy (RP) (2.2%) or radical radiotherapy (RT) (3.4%); 48 (27.5%) received palliative treatment – bilateral simple orchidectomy (BSO) (13.2%), anti-androgen monotherapy (10.7%) and luteinizing hormone receptor hormone antagonist (LHRHa) injection (3.4%); 5 (2.8%) patients had active surveillance (AS) and 111 (62.4%) decided for watchful waiting (WW). Most patients died of CaP-unrelated causes. The overall and disease-specific 5-year survival were 33% and 100% for RP, 42% and 83% for RT, 10% and 48% for BSO, 12% and 100% for anti-androgen monotherapy, 67% and 100% for LHRHa, 100% and 100% for AS, and 45% and 92% for WW, respectively. Conclusions: Most patients with pT1 CaP died of CaP-unrelated causes. Treatment plan should be discussed with patients with balance of survival benefit, benefit in improving quality of life and complications of treatment.
DescriptionOral Presentation
Persistent Identifierhttp://hdl.handle.net/10722/193962
ISSN
2015 Impact Factor: 4.387
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorLai, TCTen_US
dc.contributor.authorTsu, HLJen_US
dc.contributor.authorNg, ATLen_US
dc.contributor.authorHo, KLen_US
dc.contributor.authorYiu, MKen_US
dc.date.accessioned2014-01-28T06:38:22Z-
dc.date.available2014-01-28T06:38:22Z-
dc.date.issued2014en_US
dc.identifier.citationHong Kong Urological Association Annual Scientific Meeting, Hong Kong, 10 November 2013. In BJU International, 2014, v. 113 n. Suppl. S1, p. 8en_US
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/193962-
dc.descriptionOral Presentation-
dc.description.abstractObjective: To review the treatment modality and outcome of patients with pT1 CaP. Patients & Methods: Data of transurethral resection of prostate (TURP) performed from April 2000 to December 2009 were reviewed. Pathological results of resected specimen were reviewed on electronic patient record (ePR) system and data of patients with pT1 CaP were retrieved. Kaplan-Meier model was used to compare survival. Results: During the period, 178 patients were diagnosed pT1 prostate cancer with median follow-up time of 57.5 months. Median age at TURP was 77 years old. 97 (54.5%) patients had pT1a CaP and 65 (36.5%) had pT1b CaP; extent of tumour involvement was not reported in 16 (9%) specimens. 9 (5.1%) patients underwent curative treatment – radical prostatectomy (RP) (2.2%) or radical radiotherapy (RT) (3.4%); 48 (27.5%) received palliative treatment – bilateral simple orchidectomy (BSO) (13.2%), anti-androgen monotherapy (10.7%) and luteinizing hormone receptor hormone antagonist (LHRHa) injection (3.4%); 5 (2.8%) patients had active surveillance (AS) and 111 (62.4%) decided for watchful waiting (WW). Most patients died of CaP-unrelated causes. The overall and disease-specific 5-year survival were 33% and 100% for RP, 42% and 83% for RT, 10% and 48% for BSO, 12% and 100% for anti-androgen monotherapy, 67% and 100% for LHRHa, 100% and 100% for AS, and 45% and 92% for WW, respectively. Conclusions: Most patients with pT1 CaP died of CaP-unrelated causes. Treatment plan should be discussed with patients with balance of survival benefit, benefit in improving quality of life and complications of treatment.-
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU Internationalen_US
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.titleHow have we treated pathological T1 (pT1) prostate cancer (CaP) in recent 10 years?en_US
dc.typeConference_Paperen_US
dc.identifier.emailTsu, HLJ: jamestsu@hku.hken_US
dc.identifier.emailHo, KL: hkl218@hkucc.hku.hken_US
dc.identifier.emailYiu, MK: pmkyiu@hku.hken_US
dc.identifier.doi10.1111/bju.12606-
dc.identifier.hkuros227502en_US
dc.identifier.volume113-
dc.identifier.issueSuppl. S1-
dc.identifier.spage8-
dc.identifier.epage8-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats